Piper Jaffray Downgrades ResMed (RMD) to Neutral

Go back to Piper Jaffray Downgrades ResMed (RMD) to Neutral

Macquarie Upgrades ResMed (RMD) to Neutral

April 28, 2016 7:08 AM EDT

Macquarie upgraded ResMed (NYSE: RMD) from Underperform to Neutral.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $56.65 yesterday.

... More

ResMed (RMD) Misses Q3 EPS by 1c

April 26, 2016 4:14 PM EDT

ResMed (NYSE: RMD) reported Q3 EPS of $0.68, $0.01 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $453.9 million versus the consensus estimate of $455.88 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

... More